ArticleInternational journal of molecular sciences2021
Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction.
Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- A systematic review of therapeutic procedures for the treatment of morphea and systemic sclerosis.Lasers in medical science · 2026Pooled it
- Targeting Fibrosis in Arthritis Using mRNA Vaccine-Based Approach.Methods in molecular biology (Clifton, N.J.) · 2026Article
- CD8+ T cells drive myofibroblast activation and contraction via JAK/STAT3 and TGFβ signaling.iScience · 2025Article
- Depleting Autoreactive B‑Cells Using Targeted Photodynamic Therapy.ACS pharmacology & translational science · 2025Article
- Longitudinal assessment of circulating fibroblast activation protein in systemic sclerosis-associated interstitial lung disease.Arthritis research & therapy · 2025Article
- An international perspective on the future of systemic sclerosis research.Nature reviews. Rheumatology · 2025Review
- IFIT3 mediates TBK1 phosphorylation to promote activation of pDCs and exacerbate systemic sclerosis in mice.Clinical and translational medicine · 2024Article
- Fibroblast: A Novel Target for Autoimmune and Inflammatory Skin Diseases Therapeutics.Clinical reviews in allergy & immunology · 2024Review
- The Role and Application of Fibroblast Activating Protein.Current molecular medicine · 2024Review
- Immunomodulatory Effect of Hypericin-Mediated Photodynamic Therapy on Oral Cancer Cells.Pharmaceutics · 2023Article
- Fibroblast Activation Protein Alpha (FAPα) in Fibrosis: Beyond a Perspective Marker for Activated Stromal Cells?Biomolecules · 2023Review
- Article
- An updated review of the immunological mechanisms of keloid scars.Frontiers in immunology · 2023Review
- Near-infrared photoimmunotherapy: design and potential applications for cancer treatment and beyond.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
Systemic sclerosis (SSc) is a rare, severe, auto-immune disease characterized by inflammation, vasculopathy and fibrosis. Activated (myo)fibroblasts are crucial drivers of this fibrosis. By exploiting their expression of fibroblast activation protein (FAP) to perform targeted photodynamic therapy (tPDT), we can locoregionally deplete these pathogenic cells. In this study, we explored the use of FAP-tPDT in primary skin fibroblasts from SSc patients, both in 2D and 3D cultures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.